Introduction
============

Impaired peripheral oxygenation (IPO) of exercising muscles is caused by impaired circulation and/or mitochondrial function and a low arterial oxygen content, such that oxygen cannot flow adequately to myocytes.[@b1-copd-10-329] The mechanisms of IPO are quite different from those of hypoxemia, mostly due to respiratory pathology. IPO can seriously limit patients' ability to perform certain activities of daily living, and the impact of related symptoms can be quite significant.[@b2-copd-10-329]

Clinicians tend to screen for the causes of exertional dyspnea using non-invasive cardiopulmonary exercise testing (CPET).[@b1-copd-10-329],[@b3-copd-10-329]--[@b5-copd-10-329] IPO-related variables obtained from CPET include peak oxygen uptake $({\overset{˙}{V}O}_{2}) < 85\%$ predicted, anaerobic threshold $< 40\%{\overset{˙}{V}O}_{2\max}$ predicted, ${\overset{˙}{V}O}_{2} - \text{work}$ rate slope \<8.6 mL/watt, oxygen pulse \<80% predicted, and ventilatory equivalents for O~2~ and CO~2~ at nadirs of \>31 and \>34, respectively.[@b1-copd-10-329]

These six individual IPO variables represented cardiovascular parameters, but are reported to be non-specific in discriminating chronic obstructive pulmonary disease (COPD) with and without chronic circulatory changes[@b6-copd-10-329]--[@b8-copd-10-329] using invasive pulmonary artery catheterization.[@b7-copd-10-329],[@b8-copd-10-329] However, at present, it is not clear how we can effectively interpret the algorithm since some of the six variables may be normal while others are abnormal. We hypothesized that patients with all six variables found to be abnormal would have worse cardiovascular function than those with none or some having abnormal values. Our approach in this study was oriented toward interpretation of the CPET report, and we found that this approach may be more useful when evaluating IPO-related variables with regard to their clinical implications.

Materials and methods
=====================

Study design
------------

In this cross-sectional comparative study, the patients were divided into three groups based on six variables obtained from CPET. Patients with abnormal values for all six variables were assigned to a full IPO group, those with normal values for all six variables were assigned to a non-IPO group, and the remaining patients were assigned to an intermediate IPO group. Two-dimensional echocardiography, changes (Δ) in lactate, Δ in oxygen uptake $({\overset{˙}{V}O}_{2})$, a parameter of cardiovascular function,[@b9-copd-10-329] and arterial pH values were compared across the groups. Arterial pH values should be lower in patients with cardiovascular dysfunction than in those without cardiovascular dysfunction performing at the same exercise intensity or cardiovascular stress level. A comparison of respiratory dynamics was performed across the groups. The institutional review board of Chung Shan Medical University Hospital approved the study (approval number CS11144) and all participants provided their written informed consent. This trial is registered with the number CSH-2012-C-23 at Chung Shan Medical University Hospital, Taichung, Taiwan.

Subjects
--------

Global Initiative for Chronic Obstructive Lung Disease criteria were used to diagnose COPD.[@b10-copd-10-329] Adult patients with COPD who underwent lung function tests were enrolled only if their forced expired volume in one second (FEV~1~) was \<80% of the predicted value and their FEV~1~/forced vital capacity ratio was \<70%. If they agreed, they performed symptom-limited incremental CPET with arterial blood gas analysis and lactate measurements. All patients were clinically stable and had had no significant changes in medication in the month prior to performing the tests. Patients were excluded if they had significant comorbidities, such as left ventricular failure, renal failure, cancer, significant anemia, peripheral arterial occlusive disease, uncontrolled diabetes mellitus, or hypertension, or if they were participating in any physical training program during the study period.

Protocols and measurements
--------------------------

### Pulmonary function testing

FEV~1~, total lung capacity, and residual volume were measured by spirometry and plethysmography (6200 Autobox DL, Yorba Linda, CA, USA, or MasterScreen™ Body, Carefusion, Würzburg, Germany) at body temperature, ambient atmospheric pressure, and fully saturated, using the best of three technically satisfactory readings.[@b11-copd-10-329]--[@b13-copd-10-329] The diffusing capacity for carbon monoxide (D~L~CO) was measured by the single-breath technique. Direct maximum voluntary ventilation (MVV) was calculated from a 12-second maneuver of rapid and deep breathing as recommended for patients with COPD.[@b14-copd-10-329] All lung function data were obtained after inhaling 400 μg of fenoterol HCl.

### Maximum cardiopulmonary exercise testing

After acclimating to a computer-controlled and electronic-brake cycle ergometer (Medical Graphics, St Paul, MN, USA) and following a 2-minute rest period, each patient began a 2-minute period of unloaded cycling followed by a ramp-pattern exercise test to the limit of tolerance. Work rate was selected at a slope of 5--20 watts per minute based on a derived protocol formula.[@b15-copd-10-329] Twelve-lead electrocardiography, ${\overset{˙}{V}O}_{2}(\text{mL}/\min)$, ${\overset{˙}{V}{CO}}_{2}(\text{mL}/\min)$, minute ventilation, pulse rate, and oxyhemoglobin saturation were continuously measured. Blood pressure was recorded at the end of each minute and at the point where the patient reported having reached peak exercise. A dyspnea score was obtained using the Borg scale by asking the patients about their dyspnea levels while they were performing the ramp-pattern exercise at the end of each minute and at peak exercise. Please refer to Chuang and Lin[@b16-copd-10-329] for the anaerobic threshold, oxyhemoglobin saturation, calibrations of the pneumotachograph and O~2~ and CO~2~ analyzers, and ${\overset{˙}{V}O}_{2\text{peak}}$ prediction equations.

The ${\overset{˙}{V}O}_{2\text{peak}}$ achieved by patients was the highest recorded value averaged over the last 15 seconds of loaded exercise and designated as ${\overset{˙}{V}O}_{2\text{peak}}$ or ${\overset{˙}{V}O}_{2\max}$.[@b15-copd-10-329]

Maximum exercise effort achieved was a prerequisite for final analysis.[@b4-copd-10-329],[@b5-copd-10-329],[@b17-copd-10-329] Each criterion at peak exercise, such as respiratory exchange ratio ≥1.09, heart rate ≥85% of predicted maximum, pH ≤7.35, bicarbonate (HCO~3~^−^) concentration ≤21 mEq/L, change in HCO~3~^−^ concentration between rest and peak exercise ≥4 mEq/L, and change in lactate concentration between rest and peak exercise ≥4 mEq/L represented one point. The maximum effort level was scored from 1 to 6 points. The accumulated points, representing the effort level of exercise, were compared across the groups.

Exercise intensity or cardiovascular stress level was defined as follows: $$\begin{array}{l}
\text{Exercise~intensity~or~cardiovascular~stress~level} \\
\end{array} = \frac{\text{Heart~ratte~at~peak~exercise}}{\text{Heart~rate~predicted~maximum}}$$where heart rate predicted maximum =220 -- age.

Ventilatory limitation was defined as either \<30% or \<11--15 L/min breathing reserve, calculated as follows:[@b1-copd-10-329],[@b4-copd-10-329] $$\text{Breathing~reserve} = 1 - {\overset{˙}{V}}_{\text{Epeak}}/\text{direct~MVV}$$where ${\overset{˙}{V}}_{\text{Epeak}}/\text{direct~MVV}$ indicates ${\overset{˙}{V}}_{E}$ demand/capacity ratio. $$\begin{array}{l}
\text{Mean~inspiratory\ tidal~flow~rate} \\
\end{array} = \frac{\text{Tidal~volume~}(V_{T})(L)}{\text{Inspiratory~time~}{(\text{seconds})}^{18}}$$ $$\begin{array}{l}
\text{Rapid~shallow\ breathing~index} \\
\end{array} = \frac{\text{Breathing~frequency~}(\text{breath}/\text{min})}{V_{T}{(L)}^{19}}$$

### Two-dimensional echocardiography

Two-dimensional echocardiography (iE33, Philips, Seattle, WA, USA) was performed within 4 weeks before or after CPET by two experienced cardiologists who were blinded to the clinical data, lung function, and CPET reports. If there were acute exacerbations of COPD in the time between the two tests, one of the tests would be postponed. Parasternal, apical, and subcostal studies were conducted, and the definition of cor pulmonale was used according to previous reports.[@b20-copd-10-329],[@b21-copd-10-329]

### Arterial blood sampling and lactate determination

Brachial artery blood samples were drawn via an arterial catheter connected to a pressure transducer within the last 15 seconds of each minute after the start of exercise to the peak of exercise.[@b22-copd-10-329] Whole blood lactate was also analyzed (YSI Inc, Yellow Springs, OH, USA).

At the peak of exercise, the dead space to tidal volume ratio (V~D~/V~T~) was calculated using a standard formula.[@b23-copd-10-329]

The slopes of lactate as a function of ${\overset{˙}{V}O}_{2}$ calculated using linear regression $(\Delta\text{lactate}/\Delta{\overset{˙}{V}O}_{2})$ were compared across the groups.

Statistical analysis
--------------------

The data are shown as the mean ± standard deviation or median (interquartile range). Analysis of variance was initially considered for comparing the means across the groups; however, there were no patients in the non-IPO group. Therefore, only two groups were established. Thus, the unpaired-*t*-test or Mann--Whitney *U*-test was used to compare the means between the two independent groups. Fisher's Exact test for contingency tables was used to compare the stages of COPD between the two groups. A *P*\<0.05 was considered to be statistically significant, and *P*\<0.1 but *P*\>0.05 was considered to have a trend to be significant.[@b24-copd-10-329] All statistical procedures were performed using SAS software package version 9.3 (SAS Institute Inc, Cary, NC, USA).

Results
=======

Fifty-eight consecutive male patients of mean age 64.6±6.1 years were enrolled in the study. After excluding one patient who did not reach the maximum exercise level when performing CPET, 14 patients were assigned to the IPO group, no patients were assigned to the non-IPO group, and the other 43 patients were assigned to the intermediate IPO group ([Table 1](#t1-copd-10-329){ref-type="table"}). For the sake of simplicity, the latter two groups were deemed to be non-IPO groups. [Table 2](#t2-copd-10-329){ref-type="table"} presents the distribution of the six variables regarding the abnormal values for the non-IPO groups. The IPO and non-IPO groups had similar stages of COPD severity. The IPO group had more hyperinflated lungs and lower D~L~CO (*P*=0.05 to *P*\<0.01; [Table 1](#t1-copd-10-329){ref-type="table"}). Both groups performed at a similar level of maximum exercise effort.

No patient experienced an acute exacerbation in the time interval between echocardiography and CPET. [Table 3](#t3-copd-10-329){ref-type="table"} shows that the two-dimensional echocardiographic findings, including left ventricular ejection fraction and right ventricular morphology, were similar between the two groups (all *P*\>0.05).

The heart rate percentage predicted maximum at peak exercise was similar between the two groups (IPO group: 77%±14% versus non-IPO group: 82%±10%, *P*=0.26). pH levels were higher at anaerobic threshold and peak exercise in the IPO group (*P*=0.007 and *P*=0.0007, respectively), with a smaller decrease in HCO~3~^−^ concentration and increase in lactate concentration (3.6±0.5 mmol/L versus 5.7±0.3 mmol/L, *P*=0.02, and 1.4±1.8 mmol/L versus 2.9±1.8 mmol/L, *P*=0.003, respectively). The slopes of $\Delta\text{lactate}/\Delta{\overset{˙}{V}O}_{2}$ were similar between the two groups (2.4 \[error 0.15\] versus 2.3 \[error 0.1\] mmol/L, not statistically significant).

The IPO group had a rapid increase in ${\overset{˙}{V}}_{E}$ but slower expansion of tidal volume in response to exercise ([Figure 1A and D](#f1-copd-10-329){ref-type="fig"}, both *P*\<0.05). The IPO group had a significantly lower ${\overset{˙}{V}}_{E}$ demand/capacity ratio (*P*\<0.05) with slower inspiratory tidal flow and lower V~T~/total lung capacity expansion at both anaerobic threshold and peak exercise ([Figure 1B, C, and E](#f1-copd-10-329){ref-type="fig"}, *P*\<0.01 and *P*\<0.05, and both *P*≤0.001, respectively) and higher V~D~/V~T~, rapid shallow breathing index, and $\text{Borg}/{\overset{˙}{V}O}_{2}$ in the IPO group at peak exercise ([Figure 1F--H](#f1-copd-10-329){ref-type="fig"}, *P*\<0.001, *P*\<0.05, and *P*\<0.01, respectively).

Discussion
==========

In this study, COPD patients with full IPO and those with non-IPO had similarly impaired forced vital capacity, FEV~1~, and COPD severity ([Table 1](#t1-copd-10-329){ref-type="table"}). Both groups had different exercise capacity with very different cardiovascular exercise variables ([Table 1](#t1-copd-10-329){ref-type="table"}), but were similar in terms of cardiovascular function measured by two-dimensional echocardiography and $\Delta\text{lactate}/\Delta{\overset{˙}{V}O}_{2}$ ([Table 3](#t3-copd-10-329){ref-type="table"}). These findings suggest that cardiovascular variables on CPET cannot predict cardiac function morphologically. We therefore further differentiated the mechanism of full IPO and non-IPO during exercise. We found that patients with IPO had much poorer airflow and lung expansion and a greater perception of breathlessness ([Figure 1](#f1-copd-10-329){ref-type="fig"}).

Left ventricular performance has been reported not to be impaired in COPD patients.[@b25-copd-10-329] A previous study reported that there were no differences in oxygen uptake, work rate, oxygen pulse, and heart rate at peak exercise between patients with and without pulmonary arterial hypertension.[@b8-copd-10-329] The authors concluded that ventilatory limitation itself was the primary factor causing exercise intolerance in COPD patients. Circulatory impairment is not usually a limiting factor for exercise intolerance in patients with COPD unless complications of severe pulmonary hypertension are involved.[@b26-copd-10-329] The cardiovascular response to exercise was constrained, but not impaired, by dynamic hyperinflation or intrathoracic pressure swings limiting ventilation in COPD patients.[@b27-copd-10-329]--[@b29-copd-10-329] A study using multiple regression analysis showed that ventilatory inefficiency was not caused by oxygen uptake, work rate, oxygen pulse, or circulatory power at peak exercise, but was related to expiratory flow limitations and dynamic hyperinflation,[@b30-copd-10-329] which is consistent with other reports.[@b31-copd-10-329],[@b32-copd-10-329] Although all of the variables found in previous reports were comprehensive, they cannot be directly used when interpreting a CPET report. Our approach to the present study was oriented toward interpretation of the CPET.

We did not use pulmonary arterial hypertension as a study criterion because of the invasiveness of pulmonary arterial catheterization. Instead, we attempted to use the six non-invasive variables relating to circulatory function to categorize our COPD patients. We found that the circulatory function of the IPO patients was similar to that of the non-IPO patients according to a two-dimensional echocardiography study and by utilizing the slope of $\Delta\text{lactate}/\Delta{\overset{˙}{V}O}_{2}$, which is a marker of cardiovascular impairment.[@b30-copd-10-329] In addition, relatively low changes in HCO~3~^−^ and lactate concentrations and higher pH levels at peak exercise in the IPO group did not support cardiovascular limitations as being the primary factor of exercise limitation.

Resting FEV~1~, D~L~CO, peak inspiratory pressure, and exertional maximum ${\overset{˙}{V}}_{E}$ play a pivotal role in exercise intolerance in patients with COPD.[@b33-copd-10-329],[@b34-copd-10-329] In the present study, the IPO group showed a lower ${\overset{˙}{V}}_{E}$ demand/capacity, probably due to the slower inspiratory tidal flow not able to adequately increase ${\overset{˙}{V}}_{E}$ further in response to exercise, thereby reaching the ventilatory limit at an earlier stage. The slower inspiratory tidal flow and poorer tidal volume expansion might be due to higher tension of the diaphragm caused by increased V~D~/V~T~ when approaching peak exercise ([Figure 2](#f2-copd-10-329){ref-type="fig"})~.~ This notion is supported by studies in lung volume reduction surgery and bronchodilator use showing decreases in V~D~/V~T~ resulting in airflow improvement.[@b31-copd-10-329],[@b32-copd-10-329] Increased V~D~/V~T~ contributes to dynamic hyperinflation,[@b35-copd-10-329] thereby resulting in more rapid shallow breathing and a greater perception of dyspnea ([Figure 1G and H](#f1-copd-10-329){ref-type="fig"}). In the present study, a strong statistical power of 0.98 for V~D~/V~T~ was estimated, given 14 subjects with a mean V~D~/V~T~ of 0.51±0.09 in the IPO group and of 0.4±0.09 in the non-IPO group, and the probability of type I error of 0.05.

Study limitations
-----------------

There are a number of limitations in this study that are worthy of note. First, our COPD cohort was comprised exclusively of males, and as such the results cannot be extrapolated to females. However, it should be noted that the incidence of COPD is relatively low in Taiwanese females. Second, IPO includes impairment of cardiac, hemoglobin, and/or peripheral vascular function, and as a result, IPO cannot be fully evaluated by two-dimensional echocardiography. Further study of the peripheral circulation using near-infrared spectroscopy during exercise might be helpful.[@b36-copd-10-329] Moreover, cardiac function at rest as evaluated by two-dimensional echocardiography may not represent cardiac function during exercise. However, performing an echocardiographic examination while the subject is exercising is technically difficult. Stress echocardiography using pharmacological agents is feasible; however, cardiac performance using this modality is different from that seen during exercise. Third, the patient grouping in this study is not precise, given that some patients in the non-IPO group had abnormal values in some of the variables relevant to IPO. Since none of our 57 patients had all six variables in the normal range, 1,000 patients or more would be required to identify 20 with normal values in all six variables. Fourth, one may argue that using ${\overset{˙}{V}}_{E}/{\overset{˙}{V}{CO}}_{2}$ alone instead of the six IPO-related variables might draw similar conclusions to the study. However, this is another issue, and ${\overset{˙}{V}}_{E}/{\overset{˙}{V}{CO}}_{2}$ alone cannot represent IPO. Finally, this study did not evaluate intrapulmonary shunt during exercise, although this may not be an issue given that there was no difference in partial pressure of arterial oxygen at peak exercise between the two groups (IPO 68.6±13.1 mmHg versus non-IPO group 71±15.1 mmHg, not statistically significant).[@b37-copd-10-329]

Conclusion
==========

Although the six variables used herein are related to IPO or circulatory function, they are inconsistent with the findings of two-dimensional echocardiography and $\Delta\text{lactate}/\Delta{\overset{˙}{V}O}_{2}$ in patients with COPD. Further analysis shows that the mechanisms of exercise intolerance in COPD-IPO patients are primarily due to derangements in airflow and/or dead space ventilation. Given the strength of our findings, this study might help with the interpretation of CPET reports for COPD patients.
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![Findings in 14 patients with COPD complicated by IPO (solid line and solid circle symbol) and 43 patients with COPD complicated by non-IPO (dashed line and open circle symbol) performing incremental cardiopulmonary exercise testing.\
**Notes:** (**A**) Minute ventilation ( ${\overset{˙}{V}}_{E}$) as a function of ${\overset{˙}{V}O}_{2}\%$ predicted maximum. (**B**) $\overset{˙}{V}E$ demand/capacity ratio as a function of ${\overset{˙}{V}O}_{2}\%$ predicted maximum. (**C**) Tidal volume/inspiratory time (V~T~/T~i~) indicating mean inspiratory flow rate as a function of ${\overset{˙}{V}O}_{2}\%$ predicted maximum. (**D**) Tidal volume (V~T~) as a function of oxygen uptake $({\overset{˙}{V}O}_{2})\%$ predicted maximum. (**E**) V~T~/total lung capacity ratio (V~T~/TLC) indicating lung expansion as a function of ${\overset{˙}{V}O}_{2}\%$ predicted maximum. (**F**) Dead space/tidal volume ratio (V~D~/V~T~) as a function of ${\overset{˙}{V}O}_{2}\%$ predicted maximum. (**G**) Respiratory frequency/tidal volume (RR/V~T~) indicating the rapid shallow breathing index as a function of ${\overset{˙}{V}O}_{2}\%$ predicted maximum. (**H**) Borg scores at peak exercise normalized with peak ${\overset{˙}{V}O}_{2}$ indicating perception of dyspnea as a function of ${\overset{˙}{V}O}_{2}\%$ predicted maximum. All circles indicate the group mean at rest, anaerobic threshold, and peak exercise, respectively; bars indicate standard errors. Between-group comparisons: \**P*\<0.05; \*\**P*\<0.01; \*\*\**P* ≤0.001.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; IPO, impaired peripheral oxygenation; max, maximum; pred, predicted.](copd-10-329Fig1){#f1-copd-10-329}

![Flow chart showing the deductive mechanism of ventilatory dysfunction and perception of dyspnea at peak exercise in patients with chronic obstructive pulmonary disease complicated with impaired peripheral oxygenation.\
**Notes:** ↑, increased; ↓, decreased. Increased or decreased means increase or decrease when compared to the non-IPO group.\
**Abbreviations:** V~D~/V~T~, dead space to tidal volume ratio; ${\overset{˙}{V}}_{E}$, minute ventilation; V~T~, tidal volume.](copd-10-329Fig2){#f2-copd-10-329}

###### 

Variables related to impaired peripheral oxygenation and selected clinical characteristics and lung function test data in patients with COPD

                                                                                                IPO         Non-IPO     *P*-value
  --------------------------------------------------------------------------------------------- ----------- ----------- -----------
  Age, years                                                                                    62.9±5.9    65.2±6.1    NS
  Height, cm                                                                                    168.2±6.1   164.3±5.8   0.05
  Body mass index, kg/m^2^                                                                      21.3±3.2    22.9±3.6    0.01
  Triceps skin thickness, mm                                                                    6±2.7       8.7±5.3     0.02
  Cigarette, pack-years                                                                         38.5±17.6   42.9±18.4   NS
  Hemoglobin, g/dL                                                                              14.3±2.1    15.2±1.3    NS
  FVC (L)                                                                                       2.58±0.65   2.63±0.73   NS
  FEV~1~ (L)                                                                                    1.21±0.64   1.3±0.48    NS
  FEV~1~/FVC, %                                                                                 48±18       50±12       NS
  COPD stage I/II/III/IV, n                                                                     1/4/6/3     2/23/15/3   NS
  TLC, L                                                                                        6.99±1.07   6.26±0.87   0.04
  RV, L                                                                                         4.35±0.97   3.5±0.69    0.01
  RV/TLC, %                                                                                     62±9        56±9        0.05
  FRC, L                                                                                        5.34±1      4.51±0.79   0.02
  D~L~CO/D~L~CO~pred~, %                                                                        57±21       79±19       0.003
  IPO criteria                                                                                                          
    ${\overset{˙}{V}O}_{2\text{peak}}/\text{pred}\ {\overset{˙}{V}O}_{2\max}$, % (≥ or \<85%)   47±12       77±15       
   Anerobic threshold/pred ${\overset{˙}{V}O}_{2\max}( \geq \text{or} < 40\%)$                  24±6        37±10       
    ${\overset{˙}{V}O}_{2}\text{-work}$ rate ratio, mL/watt (≥ or \<8.6)                        5.6±2.5     8±1.5       
   Oxygen pulse~peak~, % pred maximum (≥ or \<80%)                                              60±12       95±18       
   Ventilatory equivalent for O~2nadir~ (≤ or \>34)                                             40.4±5.4    34.2±6.5    
   Ventilatory equivalent for CO~2nadir~ (≤ or \>31)                                            41.8±4.9    32.5±5.7    
  Maximum exercise effort level, point (AU)                                                     1.9±1.8     3.1±2.1     NS

**Notes:** Groups were compared using the unpaired-*t*-test. Between-group comparisons of RV were performed using the Mann--Whitney *U-*test.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; IPO, impaired peripheral oxygenation; non-IPO, patients failing to fit IPO criteria; FVC, forced vital capacity; FEV~1~, forced expired volume in one second; D~L~CO, diffusing capacity for carbon monoxide; AU, arbitrary unit; TLC, total lung capacity; RV, residual volume; FRC, functional residual capacity; NS, not statistically significant; pred, predicted.

###### 

Distribution of the six variables regarding IPO criteria for the non-IPO group (n=43[\*](#tfn3-copd-10-329){ref-type="table-fn"})

  Subjects having                                                                                        n
  ------------------------------------------------------------------------------------------------------ ----
  Any 5 abnormal of 6 criteria                                                                           9
  Any 4 abnormal of 6 criteria                                                                           7
  Any 3 abnormal of 6 criteria                                                                           9
  Any 2 abnormal of 6 criteria                                                                           16
  Any 1 abnormal of 6 criteria                                                                           1
  ${{\overset{˙}{V}O}_{2\text{peak}}/\text{pred}}\mspace{9mu}{{\overset{˙}{V}O}_{2\text{max}} < 85\%}$   29
  Anerobic threshold/pred $\overset{˙}{V}\text{O}_{2\max} < 40\%$                                        24
  ${\overset{˙}{V}O}_{2}\text{-work}$ rate ratio \<8.6 mL/watt                                           25
  Oxygen pulse~peak~ % pred maximum \<80%                                                                8
  Ventilatory equivalent for O~2nadir~ \>31                                                              24
  Ventilatory equivalent for CO~2nadir~ \>34                                                             12

**Notes:**

Technical difficulty was encountered in one subject. IPO indicates impaired peripheral oxygenation or patients with six variables in the abnormal range; non-IPO indicates patients failing to fit IPO criteria and having from one criterion with an abnormal value to five criteria with abnormal values. The six criteria were ${\overset{˙}{V}O}_{2\text{peak}}/\text{pred}\ {\overset{˙}{V}O}_{2\max} < 85\%$, anerobic threshold/pred ${\overset{˙}{V}O}_{2} - \text{work} < 40\%$ rate ratio \<8.6 mL/watt, oxygen pulse~peak~ % pred maximum \<80%, ventilatory equivalent for O~2nadir~ \>31, and ventilatory equivalent for CO2nadir \>34

**Abbreviations:** IPO, impaired peripheral oxygenation; pred, predicted.

###### 

Two-dimensional echocardiography results

  Variable                                                                          IPO    Non-IPO   *P*-value
  --------------------------------------------------------------------------------- ------ --------- -----------
  Left ventricular ejection fraction, %                                             69±5   67±6      NS
  Apical four-chamber view[\*](#tfn6-copd-10-329){ref-type="table-fn"}, yes/no                       
   EDRV \>15 cm^2^                                                                  3/9    15/23     NS
   ESRV \>10 cm^2^                                                                  0/12   5/33      NS
  Subcostal four-chamber view[\*](#tfn6-copd-10-329){ref-type="table-fn"}, yes/no                    
   EDRV \>13 cm^2^                                                                  6/6    28/10     NS
   ESRV \>8 cm^2^                                                                   7/5    15/23     NS
  Long and short axes view[\*](#tfn6-copd-10-329){ref-type="table-fn"}, yes/no                       
   Paradoxical motion of interventricular septum                                    0/12   2/36      NS
   Right ventricular free wall thickness \>4 mm                                     10/2   31/7      NS
   Tricuspid regurgitation[\*](#tfn6-copd-10-329){ref-type="table-fn"}, yes/no      8/4    30/8      NS
   Pulmonary regurgitation[\*](#tfn6-copd-10-329){ref-type="table-fn"}, yes/no      0/12   3/37      NS

**Notes:**

Some missing data.

The definitions of EDRV and ESRV were from Bertoli et al[@b20-copd-10-329] and Danchin et al.[@b21-copd-10-329]

**Abbreviations:** IPO, impaired peripheral oxygenation; ED, end-diastolic; RV, right ventricular; ES, end-systolic; NS, not statistically significant.
